Please ensure Javascript is enabled for purposes of website accessibility

You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018

By Keith Speights - Updated Nov 13, 2017 at 7:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If he's right, the big biotech stock is potentially poised for a huge run.

No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (GILD 0.82%) CEO John Milligan actually did make a prediction about 2018. And it really was stunning, at least considering the context of where the company has been and is right now.

Gilead's revenue continues to plunge, with third-quarter sales dropping more than 13%. Its earnings are still sinking, too: The biotech reported an 18% year-over-year decline in net income in the third quarter. For quite a while, Gilead's management team has stated that they weren't sure when the root cause behind the company's deteriorating numbers, slumping sales for its hepatitis C virus (HCV) franchise, would stabilize.

But when Milligan was asked at the Credit Suisse conference held in Scottsdale, Ariz., on Tuesday if 2018 could be a flattening or stabilizing year, he replied that it could be. What he said in his response was even more surprising -- perhaps even shocking. Milligan thinks that next year could be "the beginning of a growth phase" for Gilead Sciences. What's behind Milligan's optimism?

2018 written beneath wood blocks with arrow pointing up

Image source: Getty Images.

Smooth sailing ahead in HCV 

Believe it or not, Milligan thinks that AbbVie's (ABBV 0.37%) introduction of its new HCV drug, Mavyret, "sets the stage for smoothness to HCV sales for the future." Milligan acknowledged that AbbVie's pricing for its new drug will hurt Gilead in the fourth quarter of 2017 and into next year. So why does he think there will be smooth sailing ahead? For the first time in a long time, Milligan doesn't "see anything on the horizon that will be disruptive" in HCV.

What appears to be shaping up, in Milligan's view, is a one-on-one battle in HCV between AbbVie and Gilead Sciences. He said that most of the HCV drugs have about the same net price now. With pricing roughly at parity, it will come down to which HCV therapy works best for patients. Milligan thinks Epclusa matches up well against all other HCV drugs and in particular will "stack up very well against AbbVie." 

Expected launch of the best HIV drug ever

Milligan was asked if Gilead's bictegravir/F/TAF combination was as good as it gets in treating HIV. His response: "Yes." That's a bold statement, considering the tremendous success Gilead has had with its HIV drugs through the years. However, Milligan backed up his confidence by ticking off a list of pluses for the bictegravir/F/TAF combo.

At the top of the list for Milligan was that the combo requires "very few compromises." The bictegravir/F/TAF combo doesn't have worrisome interactions and is, in Milligan's words, "a very forgiving regimen." He thinks the single pill taken once daily with great efficacy and a solid safety profile will prove to be very appealing to both patients and physicians. Milligan predicted that bictegravir/F/TAF will become the "most important product out there" in the HIV market, assuming it wins approval as expected in February.

Growth for Yescarta

Another reason behind Milligan's prediction of 2018 as a year for Gilead to return to growth is the potential for Yescarta. Gilead picked up the chimeric antigen T-cell (CAR-T) therapy with its acquisition of Kite Pharma. However, the prospects for Yescarta next year won't be nearly as important to a possible turnaround for Gilead as stabilization for its HCV franchise and continued success in HIV would be.

Milligan noted that there will be a controlled launch of Yescarta. Sites must be trained on how to use the CAR-T therapy first, and then certified before accepting any patients. There were 13 sites in the first couple of weeks after the FDA approval of Yescarta. Milligan said that there would be more than 70 sites certified to treat patients with Yescarta by this time next year. While Gilead will see some incremental growth from Yescarts in 2018, its CAR-T program acquired from Kite will be more important to the company over the longer term. 

Man holding jigsaw puzzle piece with question mark on it

Image source: Getty Images.

Is Milligan right?

Could 2018 really bring the beginning of a return to growth for Gilead Sciences as Milligan predicts? Yes -- but I'd put heavy emphasis on the word "beginning." 

I suspect that Milligan's view that the company will begin to see stabilization in the HCV market next year is probably right. However, Gilead will still feel the impact of AbbVie's launch of Mavyret in the early part of 2018. Also, the real key to stabilization depends on patient starts on HCV therapy. While the decline in patient starts in the second half of 2017 has been better than expected, there hasn't been stabilization yet. 

Regarding the bictegravir/F/TAF combo, however, I don't doubt at all that Milligan's optimism is well founded. Sure, there will be some cannibalization of Gilead's current HIV products, but this really could be one the biotech's biggest winners ever. 

Gilead's shares currently trade at less than 10.5 times expected earnings. Even a hint that earnings growth could be coming back in the second half of 2018 would generate a lot of enthusiasm among investors. The conversation could then turn to Gilead's pipeline, especially its non-alcoholic steatohepatitis candidates, which hold tremendous potential for the future.

If Milligan is right that Gilead will start its return to growth next year, look for its stock to make a big comeback in 2018. 

Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51
AbbVie Inc. Stock Quote
AbbVie Inc.
$142.60 (0.37%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.